FRLN — Freeline Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00Brief: Forcefield Therapeutics Signs Exclusive Patent With Freeline Therapeutics
Freeline Therapeutics Holdings PLC expected to post a loss of 28 cents a share - Earnings Preview
Brief: Freeline Receives Approval To Transfer To Nasdaq Capital Market
Freeline Therapeutics Holdings PLC reports results for the quarter ended in September - Earnings Summary
Brief: Freeline Reports Q3 2022 Financial Results
Brief: Freeline Initiates Dosing Of Second Cohort In Marvel-1 Trial Of Flt190 Gene Therapy Candidate For People With Fabry Disease
Freeline Therapeutics Holdings PLC reports results for the quarter ended in June - Earnings Summary
Brief: Freeline Therapeutics reports Q2 results
Brief: New England Journal Of Medicine Publishes Positive Long-Term Data On Freeline’S Gene Therapy Candidate Flt180a For People With Hemophilia B
Brief: Freeline Therapeutics Says Positive Initial Clinical Data From B-Lieve Dose-Confirmation Trial For Flt180a In Hemophilia B Presented At ISTH Congress
Brief: Freeline Initiates Dosing Of Second Cohort In B-Lieve Dose Confirmation Trial Of FLT180A In Hemophilia B
Brief: Freeline Reports First Quarter 2022 Results And Business Highlights
Brief: Freeline Appoints Paul Schneider As CFO
Freeline Therapeutics Holdings PLC reports results for the quarter ended in December - Earnings Summary
Brief: Freeline Reports Full Year 2021 Financial Results And Business Highlights
Freeline Therapeutics Holdings PLC expected to post a loss of 68 cents a share - Earnings Preview
Freeline Therapeutics climbs after healthcare group Syncona's unit reports majority stake
Brief: Freeline Therapeutics Holdings PLC Announces Updated Development Plan And Timelines For FLT190 For People With Fabry Disease
Brief: Freeline Announces $26.1 Mln Registered Direct Offering Of American Depositary Shares